Edition:
United Kingdom

Teligent Inc (TLGT.OQ)

TLGT.OQ on NASDAQ Stock Exchange Global Select Market

3.92USD
15 Dec 2017
Change (% chg)

$0.07 (+1.82%)
Prev Close
$3.85
Open
$3.85
Day's High
$3.99
Day's Low
$3.82
Volume
313,396
Avg. Vol
154,927
52-wk High
$9.53
52-wk Low
$2.82

Select another date:

Wed, Nov 22 2017

BRIEF-TELIGENT ANNOUNCES FDA GENERIC APPROVAL OF HYDROCORTISONE BUTYRATE LOTION 0.1%

* TELIGENT, INC. ANNOUNCES FIRST FDA GENERIC APPROVAL OF HYDROCORTISONE BUTYRATE LOTION 0.1%

BRIEF-TELIGENT ANNOUNCES FDA APPROVAL OF ERYTHROMYCIN TOPICAL SOLUTION USP, 2%

* TELIGENT, INC. ANNOUNCES FDA APPROVAL OF ERYTHROMYCIN TOPICAL SOLUTION USP, 2%

BRIEF-Teligent announces FDA approval of betamethasone dipropionate ointment usp (augmented), 0.05%​

* Announces FDA approval of betamethasone dipropionate ointment USP (augmented), 0.05%​

BRIEF-Teligent posts Q3 qtrly ‍loss per share $0.12​

* Q3 earnings per share view $-0.01, revenue view $19.1 million -- Thomson Reuters I/B/E/S

BRIEF-Teligent announces FDA approval of partnered ANDA for Desonide Lotion

* Teligent Inc announces FDA approval of partnered ANDA for Desonide Lotion, 0.05 pct

BRIEF-Teligent Inc announces FDA approval of triamcinolone acetonide cream USP, 0.1%

* Teligent Inc announces FDA approval of triamcinolone Acetonide Cream USP, 0.1%

BRIEF-Teligent reports FDA approval of clobetasol propionate cream USP

* Teligent Inc. Announces FDA approval of clobetasol propionate cream usp, 0.05 pct, emollient

BRIEF-Teligent Q2 adjusted loss per share $0.01

* Teligent Inc says now anticipates gross margin of 47 percent to 50 percent for year ending December 31, 2017 Source text for Eikon: Further company coverage:

BRIEF-FDA approves Teligent's Erythromycin topical gel

* Teligent Inc announces FDA approval of erythromycin topical gel usp, 2%

Select another date: